AU2001249389A1 - Modified blood clotting factors and methods of use - Google Patents

Modified blood clotting factors and methods of use

Info

Publication number
AU2001249389A1
AU2001249389A1 AU2001249389A AU4938901A AU2001249389A1 AU 2001249389 A1 AU2001249389 A1 AU 2001249389A1 AU 2001249389 A AU2001249389 A AU 2001249389A AU 4938901 A AU4938901 A AU 4938901A AU 2001249389 A1 AU2001249389 A1 AU 2001249389A1
Authority
AU
Australia
Prior art keywords
methods
blood clotting
clotting factors
modified blood
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249389A
Inventor
Rodney M. Camire
Katherine A. High
Paris Margaritis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of AU2001249389A1 publication Critical patent/AU2001249389A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AU2001249389A 2000-03-22 2001-03-22 Modified blood clotting factors and methods of use Abandoned AU2001249389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19133100P 2000-03-22 2000-03-22
US60191331 2000-03-22
PCT/US2001/009355 WO2001070763A1 (en) 2000-03-22 2001-03-22 Modified blood clotting factors and methods of use

Publications (1)

Publication Number Publication Date
AU2001249389A1 true AU2001249389A1 (en) 2001-10-03

Family

ID=22705051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249389A Abandoned AU2001249389A1 (en) 2000-03-22 2001-03-22 Modified blood clotting factors and methods of use

Country Status (3)

Country Link
US (3) US20040102388A1 (en)
AU (1) AU2001249389A1 (en)
WO (1) WO2001070763A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055110A2 (en) * 2000-10-25 2002-07-18 Genzyme Corp Methods for treating blood coagulation disorders
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US7498024B2 (en) 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US8211874B2 (en) * 2005-06-03 2012-07-03 Galderma Laboratories Inc. Inhibition of thrombin generation
MX336958B (en) * 2005-11-15 2016-02-05 Philadelphia Children Hospital METHODS AND COMPOSITIONS TO MODULATE HEMOSTASIA.
CA2573472A1 (en) * 2006-01-23 2007-07-23 Tyco Healthcare Group Lp Biodegradable hemostatic compositions
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
WO2008022151A1 (en) * 2006-08-15 2008-02-21 Inspiration Biopharmaceuticals, Inc. Prophylactic treatment of hemophilia
ES2940323T3 (en) 2008-09-15 2023-05-05 Uniqure Biopharma B V Factor IX polypeptide mutant, its uses and a method for its production
DK2529020T3 (en) * 2010-01-28 2018-08-06 Childrens Hospital Philadelphia SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
NZ605400A (en) * 2010-07-09 2015-05-29 Biogen Idec Hemophilia Inc Chimeric clotting factors
CA2850603C (en) 2011-09-30 2021-11-16 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
EP2950813B1 (en) 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition
PE20160877A1 (en) 2013-09-24 2016-09-11 Pfizer COMPOSITIONS INCLUDING HETEROGENIC POPULATIONS OF RECOMBINANT HUMAN PROTEINS OF COAGULATION FACTOR XA
JP2017509328A (en) 2014-03-21 2017-04-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Genome editing without nucleases
WO2016028872A2 (en) 2014-08-19 2016-02-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
FR3035120B1 (en) * 2015-04-15 2020-02-07 Arcadophta IMMOBILIZED PLASMINOGENASE COMPOSITION, PREPARATION METHOD, USE AND DEVICE COMPRISING SUCH COMPOSITION
BR102015012334A2 (en) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp production process of blood coagulation factor vii and blood coagulation factor vii
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2020009993A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improvements in immunogenic conjugates
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
WO2023171719A1 (en) * 2022-03-08 2023-09-14 学校法人自治医科大学 Sequence of activated protein c

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2562421B1 (en) * 1984-04-09 1989-02-17 Sandoz Sa IMPROVEMENTS ON INTERLEUKIN THERAPY
US4975282A (en) * 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
DE3682257D1 (en) * 1985-11-22 1991-12-05 Takeda Chemical Industries Ltd LIPOSOME COMPOSITION.
JP2666345B2 (en) * 1987-04-16 1997-10-22 武田薬品工業株式会社 Liposome preparation and method for producing the same
US5273876A (en) * 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
FR2638643B1 (en) * 1988-11-09 1991-04-12 Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
JPH04503306A (en) * 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション Herpes simplex virus type 1 expression vector
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5175099A (en) * 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
ATE180834T1 (en) * 1990-01-29 1999-06-15 Zymogenetics Inc ANTICOAGULANT PROTEINS
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
AU664976B2 (en) * 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AU3972893A (en) * 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
ES2152953T3 (en) * 1992-08-27 2001-02-16 Sanquin Bloedvoorziening SPECIFIC ANTIBODIES FOR A HEMOSTATIC PROTEIN, ITS USE TO ISOLATE INTACT PROTEINS, HEMOSTATIC COMPOUNDS LACK OF PROTEIN PROTEIN SEGMENTATION PRODUCTS.
US5674703A (en) * 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
EP0705334A1 (en) * 1993-06-14 1996-04-10 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
WO1995013377A1 (en) * 1993-11-12 1995-05-18 Case Western Reserve University Episomal expression vector for human gene therapy
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
CA2117668C (en) * 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
US5604090A (en) * 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5693508A (en) * 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5980886A (en) * 1994-12-14 1999-11-09 University Of Washington Recombinant vectors for reconstitution of liver
JP3770333B2 (en) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 Recombinant DNA virus and method for producing the same
US6110456A (en) * 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5695977A (en) * 1995-08-31 1997-12-09 Genetic Information Research Institute Site directed recombination
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
AU5588298A (en) * 1996-12-02 1998-06-29 Cell Genesys, Inc. Adeno-associated viral vector-mediated delivery of dna to cells of the liver
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
AT405517B (en) * 1997-02-27 1999-09-27 Immuno Ag FACTOR X-DELETION MUTANTS AND ANALOGS OF THEM
AT405516B (en) * 1997-02-27 1999-09-27 Immuno Ag FACTOR X-ANALOG WITH MODIFIED PROTEASE SPLIT
US20030207402A1 (en) * 1997-08-22 2003-11-06 Erhard Kopetzki Autocatalytically activatable zymogenic precursors of proteases and their use
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
CA2340276A1 (en) * 1998-08-28 2000-03-09 Duke University Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
US6924365B1 (en) * 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
WO2002055110A2 (en) * 2000-10-25 2002-07-18 Genzyme Corp Methods for treating blood coagulation disorders
AU2003241599A1 (en) * 2002-05-22 2003-12-12 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a

Also Published As

Publication number Publication date
US20040102388A1 (en) 2004-05-27
WO2001070763A1 (en) 2001-09-27
US20110126303A1 (en) 2011-05-26
US20180273607A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
AU2001249389A1 (en) Modified blood clotting factors and methods of use
AU2001270943A1 (en) Surgical instrument and method of using the same
AU2002211389A1 (en) Microfluidic devices and methods of use
AU2002356861A1 (en) Fibrin membrane and methods for its preparation- application to artificial skin
EP1539275A4 (en) Blood aspiration system and methods of use
AU2002215357A1 (en) Puncture resistant branch artery occlusion device and methods of use
AU2001253411A1 (en) Medical dressing assembly and associated method of using the same
EP1246654A4 (en) Arterial filter with aspiration and methods of use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
IL157577A0 (en) Disposable underpants and method of providing the same
AU2001255662A1 (en) Miniaturized surgical forceps and methods of making the same
AU2002314466A1 (en) Withasol and methods of use
AU2001259449A1 (en) Whole blood separator apparatus and method of use
AU2002320147A1 (en) Microdialysis probes and methods of use
AU3622600A (en) Metalloproteinases and methods of use therefor
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002312315A1 (en) Microfabricated surgical devices and methods of making the same
AU2001277202A1 (en) Bstp-ras/rerg protein and related reagents and methods of use thereof
AU2002366343A1 (en) Methods and systems for making disposable absorbent article having graphics
AU2001251489A1 (en) Assembly for extracorporeal blood handling and method of use
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2002216092A1 (en) Method and device for determining the topology of biological tissue
AU2001261375A1 (en) Human caspase-12 materials and methods
AU3501700A (en) Human endokine alpha and methods of use
AU2001244461A1 (en) Venous line catheter and method of operating the same